Back to Sites Gaborone CRS Site Number 12701 Address Gaborone Prevention/Treatment Trials CRS Princess Marina Hospital Plot 1836, North Ring Road Gaborone, Botswana IMPAACT Members at this Site Unoda Chakalisa CRS Coordinator Tebogo Kakhu CRS Coordinator Anthony Ogwu CRS Leader Ayotunde Omoz-Oarhe CRS Leader Tendani Gaolathe CRS Staff Loeto Mazhani CRS Staff Mompati Mmalane CRS Staff Sylvester Musa-Aisien CRS Staff Gaerolwe Masheto CTU Coordinator Shahin Lockman CTU Principal Investigator Joseph Makhema CTU Principal Investigator Sue Welsch DAIDS PO Sikhulile Moyo Laboratory Director Terence Mohammed Laboratory Manager/Supervisor Lesedi Tirelo Laboratory QA/QC Coordinator Motswedi Anderson Laboratory Technician/Technologist Rufaro Mangwarara Pharmacist Yvonne Mugodi Pharmacist Tshepho Frank Pharmacy Supervisor Urunduruka Munamava QA/QC Coordinator Tumalano Sekoto Regulatory Coordinator Taolo Modise Research Nurse Mpho Raesi Research Nurse Aida Asmelash Staff Gaerolwe Masheto Staff Tebogo Mokotedi Staff Akeem Salawu Staff Dichaba Siane Staff Ponego Ponatshego Study Coordinator Mpho Raesi Study Coordinator Studies at this Site 1077HS: HAART Standard Version of the PROMISE Study (Maternal & Infant Survival) DAIDS Number 10779 Research Area Therapeutics Study Status Participants Off Study and Primary Analysis Completed P1026S: PK in Pregnancy DAIDS Number Therapeutics Research Area Treatment Study Status Closed to Follow Up P1066: Raltegravir Safety, Tolerability, PK, & Antiretroviral Activity DAIDS Number 10495 Research Area Treatment Study Status Concluded P1072: Safety and Immunogenicity of a Live, Attenuated, Rotavirus Vaccine (RotaTeqâ„¢) in HIV-1 Infected and Uninfected Children Born to HIV-1 Infected Mothers DAIDS Number 10638 Research Area Complications & Comorbidities Study Status Concluded P1078: TB APPRISE: TB Ante vs. Postpartum Prevention with INH in HIV Seropositive mothers and their Exposed infants DAIDS Number 10732 Research Area Tuberculosis P1093: PK, Safety, Tolerability and Antiviral Activity of Dolutegravir DAIDS Number 11773 Research Area Therapeutics IMPAACT 2008: Phase I/II Multisite, Randomized, Controlled Study of Monoclonal Antibody VRC01 with Combination Antiretroviral Therapy to Promote Clearance of HIV-1-Infected Cells in Infants DAIDS Number 20735 Research Area Cure and Immunotherapy Study Status Participants Off Study and Primary Analysis Completed IMPAACT 2010: VESTED DAIDS Number 30129 Research Area Therapeutics Study Status Participants Off Study and Primary Analysis Completed IMPAACT 2016: Evaluating a Group-Based Intervention to Improve Mental Health and ART Adherence Among Youth Living with HIV in Low Resource Settings DAIDS Number 38506 Research Area Brain and Mental Health Study Status Closed to Accrual IMPAACT 2019: Phase I/II Study of the Pharmacokinetics, Safety, and Tolerability of Abacavir/Dolutegravir/Lamivudine Dispersible and Immediate Release Tablets in HIV-1-Infected Children Less than 12 Years of Age DAIDS Number 38504 Research Area Therapeutics Study Status Participants Off Study and Primary Analysis Completed Pagination Current page 1 Page 2 Next page Next
1077HS: HAART Standard Version of the PROMISE Study (Maternal & Infant Survival) DAIDS Number 10779 Research Area Therapeutics Study Status Participants Off Study and Primary Analysis Completed
P1026S: PK in Pregnancy DAIDS Number Therapeutics Research Area Treatment Study Status Closed to Follow Up
P1066: Raltegravir Safety, Tolerability, PK, & Antiretroviral Activity DAIDS Number 10495 Research Area Treatment Study Status Concluded
P1072: Safety and Immunogenicity of a Live, Attenuated, Rotavirus Vaccine (RotaTeqâ„¢) in HIV-1 Infected and Uninfected Children Born to HIV-1 Infected Mothers DAIDS Number 10638 Research Area Complications & Comorbidities Study Status Concluded
P1078: TB APPRISE: TB Ante vs. Postpartum Prevention with INH in HIV Seropositive mothers and their Exposed infants DAIDS Number 10732 Research Area Tuberculosis
P1093: PK, Safety, Tolerability and Antiviral Activity of Dolutegravir DAIDS Number 11773 Research Area Therapeutics
IMPAACT 2008: Phase I/II Multisite, Randomized, Controlled Study of Monoclonal Antibody VRC01 with Combination Antiretroviral Therapy to Promote Clearance of HIV-1-Infected Cells in Infants DAIDS Number 20735 Research Area Cure and Immunotherapy Study Status Participants Off Study and Primary Analysis Completed
IMPAACT 2010: VESTED DAIDS Number 30129 Research Area Therapeutics Study Status Participants Off Study and Primary Analysis Completed
IMPAACT 2016: Evaluating a Group-Based Intervention to Improve Mental Health and ART Adherence Among Youth Living with HIV in Low Resource Settings DAIDS Number 38506 Research Area Brain and Mental Health Study Status Closed to Accrual
IMPAACT 2019: Phase I/II Study of the Pharmacokinetics, Safety, and Tolerability of Abacavir/Dolutegravir/Lamivudine Dispersible and Immediate Release Tablets in HIV-1-Infected Children Less than 12 Years of Age DAIDS Number 38504 Research Area Therapeutics Study Status Participants Off Study and Primary Analysis Completed